首页> 美国卫生研究院文献>Frontiers in Medicine >The Laboratory-Based Intermountain Validated Exacerbation (LIVE) Score Identifies Chronic Obstructive Pulmonary Disease Patients at High Mortality Risk
【2h】

The Laboratory-Based Intermountain Validated Exacerbation (LIVE) Score Identifies Chronic Obstructive Pulmonary Disease Patients at High Mortality Risk

机译:基于实验室的山间验证加重(LIVE)评分可识别出高死亡率风险的慢性阻塞性肺疾病患者

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

>Background: Identifying COPD patients at high risk for mortality or healthcare utilization remains a challenge. A robust system for identifying high-risk COPD patients using Electronic Health Record (EHR) data would empower targeting interventions aimed at ensuring guideline compliance and multimorbidity management. The purpose of this study was to empirically derive, validate, and characterize subgroups of COPD patients based on routinely collected clinical data widely available within the EHR.>Methods: Cluster analysis was used in 5,006 patients with COPD at Intermountain to identify clusters based on a large collection of clinical variables. Recursive Partitioning (RP) was then used to determine a preferred tree that assigned patients to clusters based on a parsimonious variable subset. The mortality, COPD exacerbations, and comorbidity profile of the identified groups were examined. The findings were validated in an independent Intermountain cohort and in external cohorts from the United States Veterans Affairs (VA) and University of Chicago Medicine systems.>Measurements and Main Results: The RP algorithm identified five LIVE Scores based on laboratory values: albumin, creatinine, chloride, potassium, and hemoglobin. The groups were characterized by increasing risk of mortality. The lowest risk, LIVE Score 5 had 8% 4-year mortality vs. 56% in the highest risk LIVE Score 1 (p < 0.001). These findings were validated in the VA cohort (n = 83,134), an expanded Intermountain cohort (n = 48,871) and in the University of Chicago system (n = 3,236). Higher mortality groups also had higher COPD exacerbation rates and comorbidity rates.>Conclusions: In large clinical datasets across different organizations, the LIVE Score utilizes existing laboratory data for COPD patients, and may be used to stratify risk for mortality and COPD exacerbations.
机译:>背景:确定具有高死亡率或医疗保健风险的COPD患者仍然是一个挑战。一个强大的系统可以使用电子健康记录(EHR)数据识别高危COPD患者,从而有助于针对性干预,以确保指南的遵从性和多发病率管理。这项研究的目的是根据EHR内广泛收集的常规临床数据,以经验方式得出,验证和表征COPD患者的亚组。>方法:在Intermountain的5,006例COPD患者中进行了聚类分析根据大量临床变量来识别聚类。然后使用递归分区(RP)来确定基于简约变量子集将患者分配到聚类的首选树。检查了确定组的死亡率,COPD恶化和合并症。研究结果在独立的山间队列研究小组和美国退伍军人事务部(VA)和芝加哥大学医学系统的外部队列研究中得到了验证。>测量和主要结果: RP算法根据以下数据确定了五个LIVE得分:实验室值:白蛋白,肌酐,氯化物,钾和血红蛋白。这些组的特征是死亡风险增加。最低风险的LIVE评分5的4年死亡率为8%,而最高风险的LIVE评分1的56%(p <0.001)。这些发现在VA队列(n = 83,134),扩大的山间队列(n = 48,871)和芝加哥大学系统(n = 3,236)中得到了验证。较高的死亡率组还具有较高的COPD恶化率和合并症率。>结论:在不同组织的大型临床数据集中,LIVE Score利用了COPD患者的现有实验室数据,可用于对死亡风险进行分层和COPD恶化。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号